 I think the implication of what you're saying, logical conclusion, is that if that were to happen and if the FDA does do a kind of resurvey, reexamination or new studies that ultimately do prove safety, that you would be okay with a return to the, at least to the 2016 standards and potentially 2021. That there is a world where the FDA can make that case to satisfy your standards and then you would be accepting of the continuing use of the drug in clinics around the country?